Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Tiziana Life Sciences ( (TLSA) ).
On January 29, 2025, Tiziana Life Sciences received a notification from Nasdaq indicating non-compliance with the $1.00 Minimum Bid Price Requirement for its common shares. While this notice does not currently affect the trading of the company’s securities, Tiziana plans to monitor its stock price and may consider strategic options to meet the requirement. Failure to comply by July 28, 2025, could result in an extension of 180 days to regain compliance. The company is committed to resolving the issue to maintain its Nasdaq listing.
More about Tiziana Life Sciences
Tiziana Life Sciences LTD operates in the biotechnology industry, focusing on developing innovative therapies for cancer and autoimmune diseases. The company is headquartered in London and is publicly traded on the Nasdaq Capital Market.
YTD Price Performance: 1.03%
Average Trading Volume: 626,048
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $76.12M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.
